| Chapter title |
Prophylactic Hepatitis E Vaccine
|
|---|---|
| Chapter number | 13 |
| Book title |
Hepatitis E Virus
|
| Published in |
Advances in experimental medicine and biology, January 2016
|
| DOI | 10.1007/978-94-024-0942-0_13 |
| Pubmed ID | |
| Book ISBNs |
978-9-40-240940-6, 978-9-40-240942-0
|
| Authors |
Jun Zhang, Qinjian Zhao, Ningshao Xia, Zhang, Jun, Zhao, Qinjian, Xia, Ningshao |
| Abstract |
Hepatitis E has been increasingly recognized as an underestimated global disease burden in recent years. Subpopulations with more serious infection-associated damage or death include pregnant women, patients with basic liver diseases, and elderly persons. Vaccine would be the most effective means for prevention of HEV infection. The lack of an efficient cell culture system for HEV makes the development of classic inactive or attenuated vaccine infeasible. Hence, the recombinant vaccine approaches are explored deeply. The neutralizing sites are located almost exclusively in the capsid protein, pORF2, of the virion. Based on pORF2, many vaccine candidates showed potential of protecting primate animals; two of them were tested in human and evidenced to be well tolerated in adults and highly efficacious in preventing hepatitis E. The world's first hepatitis E vaccine, Hecolin(®) (HEV 239 vaccine), was licensed in China and launched in 2012. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 36% |
| Researcher | 3 | 27% |
| Student > Ph. D. Student | 1 | 9% |
| Student > Bachelor | 1 | 9% |
| Student > Postgraduate | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 1 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 18% |
| Veterinary Science and Veterinary Medicine | 1 | 9% |
| Immunology and Microbiology | 1 | 9% |
| Nursing and Health Professions | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 2 | 18% |